• 简

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Neogen (NEOG) Stock Climbs As Margin Repair Counters Lingering Losses

    Simply Wall St·07/31/2026 22:19:30
    语音播报

    Neogen stock jumped 4.4% to US$12.04 into the close, even though the headline earnings story is still about loss making operations. The company delivered fourth quarter revenue of US$225.3m and adjusted EBITDA margins a little above 20%, which puts the focus squarely on profitability rather than top line scale.

    Short term traders are reacting to signs of margin repair and better cash generation. Longer term holders will be weighing those improving Food Safety margins against a still weak earnings profile and forecasts that indicate continued pressure on profitability in the years ahead.

    Is Neogen a quietly mispriced recovery story, or just a low-growth stock with rising earnings risk baked in? Compare the stock's 3x P/S multiple against detailed cash flow and profitability assumptions in our valuation analysis for Neogen.

    FY 2026 Earnings Summary

    • Revenue (Q4 FY 2026 vs. Q4 FY 2025): US$225.3m vs. US$225.459m (broadly flat year on year)
    • Net Income/Loss (Q4 FY 2026 vs. Q4 FY 2025): loss of US$11.3m vs. loss of US$612.196m (material reduction in reported loss)
    • Basic EPS (Q4 FY 2026 vs. Q4 FY 2025): loss of US$0.051906 per share vs. loss of US$2.820653 per share (material reduction in loss per share)
    • Adjusted EBITDA Margin (Q4 FY 2026 vs. prior year): approximately 20.2% in Q4 FY 2026 compared with a lower margin in the prior year (management highlighted margin repair, exact prior margin not specified)

    Prefer clear visuals instead of another dense block of earnings figures and footnotes? See Neogen's full financial picture with an at-a-glance view of its profitability trends and margins in the interactive company report for Neogen.

    NasdaqGS:NEOG Trailing 12-Month Revenue & Expenses Breakdown as at Jul 2026
    NasdaqGS:NEOG Trailing 12-Month Revenue & Expenses Breakdown as at Jul 2026

    Neogen’s Bull Story Hinges On Margin Repair Milestones

    Supporters of Neogen argue that integrating 3M Food Safety, insourcing Petrifilm and tightening operations will turn the company into a higher margin, recurring revenue platform. The latest quarter gives some concrete progress on that script. Food Safety core growth of 5.8% and culture media and sanitation products growing in the high single to low double digits show customers are actually using the expanded test portfolio, not just hearing a story about it.

    The margin piece is critical for this bull case. Adjusted gross margin at 49.7% and adjusted EBITDA margin at 20.2% mark a clear step up and line up with guidance for roughly 20.5% adjusted EBITDA in FY27. Inventory is lower by about US$36m and on time in full delivery has improved, which directly supports the claim that operational fixes, not just revenue hopes, are driving the recovery narrative.

    Access the street level view of where Neogen could inflect next; the surface looks calm around US$12, but the models often disagree sharply on the outer years. Reveal where the consensus breaks and what the street is secretly modeling for the next FY with the full analyst estimates for Neogen.

    Neogen Bears Still See Earnings Power On Trial

    The core bearish worry around Neogen is that end market softness and integration friction keep earnings power structurally capped, even if Food Safety grows. This quarter does not fully disprove that. Food Safety core growth of 5.8% and a 20.2% adjusted EBITDA margin show the business is functioning more cleanly, yet group revenue is broadly flat year on year and the company still reported a loss of US$11.3m.

    Bears also argue that 3M Food Safety integration issues and Petrifilm execution could drag longer than planned. Management talks about sample collection margin repair and has Petrifilm validation and transfer milestones coming, but those are future dated and not yet reflected in the numbers. The FY27 outlook targets roughly a 20.5% adjusted EBITDA margin, which challenges the severe margin compression argument, but earnings remain dependent on further operational savings that are still in progress rather than completed.

    After a flat revenue line, a reported loss and margin repair still in progress, it is worth asking whether Neogen’s earnings risk is fully visible or just the first crack. Review the independent risk analysis for Neogen which shows 2 important warning signs

    Build Your Edge With Neogen Insights

    If Neogen's margin repair story and loss making profile have your attention, register for free with Simply Wall St and add it to a Watchlist to track price against fair value and watch how the earnings story develops. After you take a position, use the Portfolio Command Center to cut through market noise and get focused updates that matter for your holdings. For the longer term, tap into the crowd view through the Community and see how other investors are interpreting the same numbers and milestones. By surfacing potential catalysts and risks early, you give yourself a better chance to stay ahead of market reactions and make more confident decisions.

    Seeking Alternatives Beyond Neogen?

    Fresh ideas can move fast. Some stocks are building breakout momentum while they are still under the radar for now. Do your homework before the crowd catches up and act now.

    This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.